Finnhub - LLY

88 videos

Date Title Duration T A Summary Preview
Feb 19, 01:15 Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation N/A — — No analysis
Feb 18, 17:50 Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs N/A — — No analysis
Feb 18, 16:58 XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning N/A — — No analysis
Feb 18, 16:51 Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? N/A — — No analysis
Feb 18, 15:13 Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns N/A — — No analysis
Feb 18, 13:12 Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026? N/A — — No analysis
Feb 18, 13:09 Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects N/A — — No analysis
Feb 18, 12:22 Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? N/A — — No analysis
Feb 18, 11:45 Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight N/A — — No analysis
Feb 18, 11:30 Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game N/A — — No analysis
Feb 18, 11:15 Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6 N/A — — No analysis
Feb 18, 10:22 An Alzheimer’s startup emerges with $175M in venture backing N/A — — No analysis
Feb 18, 07:47 Eli Lilly's TOGETHER-PsO Open-label Phase 3B Trial Of Concomitant Use Of Taltz (Ixekizumab) And Zepbound (Tirzepatide) Compared To Taltz Alone For Moderate-to-severe Plaque Psoriasis And Obesity Met The Primary And All Key Secondary Endpoints N/A — — No analysis
Feb 18, 05:02 CSL Enters Into An Exclusive Licensing Agreement With Eli Lilly, Granting Certain Rights To Develop And Commercialize Clazakizumab For An Upfront Payment Of $100M And Potential Milestone Payments, As Well As Sales-based Royalties N/A — — No analysis
Feb 17, 22:12 Eli Lilly Preps Oral Weight-Loss Launch N/A — — No analysis
Feb 17, 22:00 Eli Lilly Reports Phase 3 Win for Retevmo in Early Lung Cancer N/A — — No analysis
Feb 17, 20:58 Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash N/A — — No analysis
Feb 17, 20:48 Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million N/A — — No analysis
Feb 17, 20:42 Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake N/A — — No analysis
Feb 17, 20:36 Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More N/A — — No analysis
Feb 17, 17:35 1 Reason I'd Buy Eli Lilly Stock and Never Sell N/A — — No analysis
Feb 17, 16:09 Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside N/A — — No analysis
Feb 17, 13:59 Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market N/A — — No analysis
Feb 17, 13:37 Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales N/A — — No analysis
Feb 17, 13:00 Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company N/A — — No analysis
Feb 17, 12:36 Novo Nordisk: The Possible Upside N/A — — No analysis
Feb 17, 10:32 Reported Earlier" 'Lilly targets India as global export hub amid booming Mounjaro sales, executive says' - Reuters N/A — — No analysis
Feb 17, 09:53 Lilly targets India as global export hub amid booming Mounjaro sales, executive says N/A — — No analysis
Feb 17, 09:01 Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup N/A — — No analysis
Feb 17, 07:42 Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients N/A — — No analysis
Feb 17, 05:06 Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum N/A — — No analysis
Feb 17, 04:40 Reported Monday, Lilly Reports Retevmo Event-Free Survival Advantage In First Randomized Phase 3 Trial Of Selective RET Kinase Inhibitor In Early-Stage RET Fusion-Positive NSCLC N/A — — No analysis
Feb 17, 04:22 Reported Monday, Eli Lilly Joins USOPC As Presenting Partner Of Team USA Athlete Recovery Program Building On Official Partner In Health Equity Role Through LA28 Olympic Games N/A — — No analysis
Feb 16, 21:05 Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? N/A — — No analysis
Feb 16, 19:00 Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery N/A — — No analysis
Feb 16, 17:02 Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages N/A — — No analysis
Feb 16, 15:26 NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock? N/A — — No analysis
Feb 16, 15:00 Lilly to participate in TD Cowen's 46th Annual Health Care Conference N/A — — No analysis
Feb 16, 14:11 How Investors Are Reacting To Eli Lilly (LLY) Building Massive Orforglipron Inventory After Strong 2025 Results N/A — — No analysis
Feb 16, 13:59 RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? N/A — — No analysis
Feb 16, 13:11 Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets N/A — — No analysis
Feb 16, 13:00 AI is disrupting drug discovery faster than expected N/A — — No analysis
Feb 16, 13:00 USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company N/A — — No analysis
Feb 16, 11:45 Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer N/A — — No analysis
Feb 16, 11:03 Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 N/A — — No analysis
Feb 16, 10:00 Theranostics earmarked as “the future” of radiopharmaceuticals N/A — — No analysis
Feb 15, 23:00 Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery N/A — — No analysis
Feb 15, 06:00 Beijing Could Focus on the Shopper in the Year of the Horse. Smart Ways to Play It. N/A — — No analysis
Feb 14, 16:06 Eli Lilly Expands Beyond GLP 1s With Orna Deal And Nvidia Alliance N/A — ✓ # LLY News Report — 2026-02-14 ## Overview | Metric | Value | |--------|-------| | **Ticker** | LLY | | **Date** | 2026-02-14 | | **Total Articles**...
Feb 14, 00:03 Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference N/A — — No analysis
Feb 13, 17:59 Eli Lilly Builds $1.5 Billion Pill Inventory N/A — — No analysis
Feb 13, 17:24 Eli Lilly Builds Orforglipron Inventory Ahead of FDA Review N/A — — No analysis
Feb 13, 15:35 Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? N/A — — No analysis
Feb 13, 14:57 Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital N/A — — No analysis
Feb 13, 14:54 Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook N/A — — No analysis
Feb 13, 14:50 Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term N/A — — No analysis
Feb 13, 14:45 CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens N/A — — No analysis
Feb 13, 14:24 Elanco Announces Updates to Board of Directors N/A — — No analysis
Feb 13, 12:42 Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device N/A — — No analysis
Feb 13, 12:13 Eli Lilly Expands Beyond GLP 1 With Cell And Genetic Therapies N/A — — No analysis
Feb 13, 08:35 Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential N/A — — No analysis
Feb 13, 06:36 Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms N/A — — No analysis
Feb 12, 19:20 Eli Lilly Stock Climbs -- Wall Street Turns Bullish on 2026 Outlook N/A — ✓ # LLY News Report — 2026-02-12 ## Overview | Metric | Value | |--------|-------| | **Ticker** | LLY | | **Date** | 2026-02-12 | | **Total Articles**...
Feb 12, 18:14 Novo Nordisk plans Wegovy vials amid obesity-drug competition N/A — — No analysis
Feb 12, 16:31 Eli Lilly & Co. stock outperforms competitors on strong trading day N/A — — No analysis
Feb 12, 15:09 The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific N/A — — No analysis
Feb 12, 13:42 How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report N/A — — No analysis
Feb 12, 13:03 VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates N/A — — No analysis
Feb 12, 13:02 'We know that consumers' behavior changes': McDonald's prepares for wider GLP-1 adoption as weight-loss pills hit market N/A — — No analysis
Feb 12, 12:02 West Pharma forecasts 2026 profit above estimates on strong demand for drug components N/A — — No analysis
Feb 12, 10:30 Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. N/A — — No analysis
Feb 12, 10:13 Eli Lilly Expands Beyond Obesity With Orna Deal And New Partnerships N/A — — No analysis
Feb 12, 08:00 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift N/A — — No analysis
Feb 12, 05:23 Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs N/A — — No analysis
Feb 12, 01:39 Inspire Medical Systems Q4 Earnings Call Highlights N/A — — No analysis
Feb 12, 00:38 Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline N/A — — No analysis
Feb 11, 23:00 PRIMECAP Management's Strategic Moves: A Closer Look at Eli Lilly and Co N/A — — No analysis
Feb 11, 21:14 Top Analyst Reports for Eli Lilly, Marriott & Fortinet N/A — — No analysis
Feb 11, 19:26 Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment N/A — — No analysis
Feb 11, 18:08 Pfizer: A Great Opportunity Post Earnings N/A — — No analysis
Feb 11, 17:57 Pharma companies left out of Trump's drug-pricing deals look for way in N/A — — No analysis
Feb 11, 16:41 'Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials' - Bloomberg N/A — — No analysis
Feb 11, 15:03 Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start N/A — — No analysis
Feb 11, 14:54 Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook? N/A — — No analysis
Feb 11, 11:25 Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs N/A — — No analysis
Feb 11, 08:59 Taking the new Wegovy pill every day is really complicated. Will patients stick with it? N/A — — No analysis
Feb 11, 05:41 The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call N/A — — No analysis
Feb 11, 04:34 Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued N/A — — No analysis